2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure Prophylaxis

By sjmartinez • October 30, 2024

Bhimraj A, Falck-Ytter Y, Kim AY, Li JZ, Baden LR, Johnson S, Shafer RW, Shoham S, Tebas P, Bedimo R, Cheng VC, Chew KW, Chiotos K, Daar ES, Dzierba AL, Glidden DV, Hardy EJ, Martin GS, MacBrayne C, Nadig N, Nakamura MM, Shumaker AH, Tien P, Loveless J, Morgan RL, Gandhi RT. 2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure Prophylaxis. Clin Infect Dis. 2024 Oct 29:ciae435. doi: 10.1093/cid/ciae435. Epub ahead of print. PMID: 39471458.

Tags: covid-19, guideline, Infectious Diseases, pemivibart, Pre-exposure prophylaxis, Publications, SARS-CoV-2

Rare mycetoma caused by Raghukumaria species, a mangrove-derived dematiaceous fungus in a kidney transplant patient

Gonzalez-Ferrer S, Yanagimoto-Ogawa L, Zhuo R, Matysiak Match CJ, Dayo A, Kang Y, Yang S. Rare mycetoma caused by Raghukumaria species, a mangrove-derived dematiaceous fungus in a[...]

Cannabis use, risk of cannabis use disorder, and anxiety and depression among bisexual patients: A comparative study of sex and sexual identity differences in a large health system

Setrakian N, Gelberg L, Koerber J, Chung UY, Akabike WN, Gorbach PM, Seamans MJ, Shoptaw S, Cerezo A, Javanbakht M. Cannabis use, risk of cannabis[...]

Host targets of candidalysin

Lin J, Filler SG. Host targets of candidalysin. PLoS Pathog. 2025 Jun 23;21(6):e1013284. doi: 10.1371/journal.ppat.1013284. PMID: 40549807; PMCID: PMC12184922.